Press releases
2024
22 February, 2024
Year-End report January-December 2023
2023
19 December, 2023
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today
14 December, 2023
Egetis’ Investor Day on December 19: Agenda and Registration Details
13 December, 2023
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA
1 December, 2023
Save the Date: Egetis to host Investor Day on December 19, 2023
10 November, 2023
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan
8 November, 2023
Interim report Q3 2023
1 November, 2023
Egetis’ Nomination Committee for the 2024 Annual General Meeting
31 October, 2023
Change in the number of shares and votes in Egetis Therapeutics
27 October, 2023
Egetis announces EMA validation of Marketing Authorisation Application for Emcitate for the treatment of MCT8 deficiency
11 October, 2023
Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm
9 October, 2023
Egetis submits marketing authorisation application for Emcitate for treatment of MCT8 deficiency to the European Medicines Agency
25 September, 2023
ReTRIACt trial design presented at the Annual Meeting of the European Society for Paediatric Endocrinology
12 September, 2023
Egetis to participate at medical conferences to increase disease awareness about MCT8 deficiency
30 August, 2023
Egetis to participate at upcoming investor conferences
22 August, 2023
Interim report Q2 2023
24 July, 2023
Egetis announces first patient included and second site activated in the pivotal ReTRIACt trial
28 June, 2023
Egetis announces site activation in the pivotal ReTRIACt trial for Emcitate® and updates timeline for the US NDA submission
16 June, 2023
Board directors in Egetis Therapeutics acquire shares